10-Q: Certara Reports Q2 2026 Results, Divests Medical Writing Business

Certara, Inc. announced its Q2 2026 financial results, reporting a net loss from continuing operations and completing the sale of its medical writing business.

Summary

• Certara, Inc. reported total revenues of $93.3 million for the three months ended June 30, 2026, a 1% increase from the prior year, driven by software revenue growth.
• The company reported a net loss from continuing operations of $6.1 million for the quarter, compared to a net income of $1.5 million in the same period last year.
• Certara completed the sale of its global medical writing and related regulatory services business to Veristat, LLC on May 8, 2026, for $69.4 million in cash, plus an additional $15 million in escrow and potential earn-out of up to $35 million.
• The divestiture resulted in an estimated pre-tax loss on sale of $65.5 million, contributing to a total loss from discontinued operations of $49.2 million for the quarter.
• For the six months ended June 30, 2026, total revenues were $187.4 million, a 2% increase year-over-year, with a net loss from continuing operations of $17.9 million.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the reported net loss from continuing operations and a significant loss from discontinued operations, despite revenue growth in software.

Positives

• Total revenues increased by 1% to $93.3 million for the three months ended June 30, 2026, driven by software revenue growth.
• Software revenues increased by 4% to $48.8 million for the three months ended June 30, 2026.
• The company completed the sale of its medical writing business, potentially allowing for a more focused strategy.
• The company has $184.1 million in cash and cash equivalents as of June 30, 2026, providing liquidity.

Negatives

• Reported a net loss from continuing operations of $6.1 million for the three months ended June 30, 2026, compared to a net income of $1.5 million in the prior year.
• Reported a net loss from continuing operations of $17.9 million for the six months ended June 30, 2026, compared to a net income of $3.0 million in the prior year.
• The divestiture of the medical writing business resulted in a significant pre-tax loss on sale of $65.5 million.
• General and administrative expenses increased by 31% to $21.9 million for the three months ended June 30, 2026, largely due to contingent consideration remeasurement.
• Services revenues decreased by 3% to $44.5 million for the three months ended June 30, 2026.

Risks

• The company faces competition in a highly fragmented market.
• Changes or delays in government regulation relating to the biopharmaceutical industry could decrease demand for services.
• Reduction in R&D spending by customers may reduce demand for products and services.
• The company depends on key personnel and may not be able to retain or recruit qualified personnel.
• Issues relating to the implementation and use of AI and machine learning could result in reputational harm or legal liability.
• The company may need additional funding if it cannot raise capital or generate sufficient cash flows.

Future Outlook

The company's future operating results depend on its ability to enter new markets, increase its customer base, and retain and expand relationships with existing customers. Investments in growth are expected to continue in scientific talent, sales and marketing, and research and development. The acceptance of model-informed biopharmaceutical discovery and development by regulatory authorities is critical to demand for its products and services.

Management Comments

• We believe our existing sources of liquidity will be sufficient to meet our working capital, capital expenditures, and contractual obligations for the foreseeable future.
• Our future capital requirements, however, will depend on many factors, including funding for potential acquisitions, investments, common stock repurchase, and other growth and strategic opportunities, which could increase our cash requirements.

Industry Context

StockSavvy.ai notes that Certara operates in the critical but highly regulated biopharmaceutical industry, where the adoption of biosimulation and model-informed drug development (MIDD) is increasingly important for accelerating drug discovery and reducing costs. The company's focus on these areas aligns with industry trends towards data-driven decision-making and the integration of AI.

Legal Proceedings

• The company does not have any pending or threatened litigation which, individually or in the aggregate, would have a material adverse effect on its condensed consolidated financial statements as of June 30, 2026.

Stakeholder Impact

• Shareholders may be concerned by the reported net losses from continuing operations and the significant loss from the discontinued operations sale.
• Employees of the divested medical writing business have transitioned to Veristat, LLC.
• Customers may benefit from Certara's continued focus on biosimulation and MIDD, potentially leading to more efficient drug development.
• Creditors' risk may be slightly elevated due to the net losses, though the company maintains substantial cash reserves.

Next Steps

• Continue to invest in scientific talent, sales and marketing, and research and development.
• Focus on core biosimulation and MIDD businesses following the divestiture.
• Monitor and adapt to evolving regulatory landscapes in the biopharmaceutical industry.
• Manage cash flow and liquidity to meet working capital, capital expenditures, and contractual obligations.

Key Dates

Recommendation

While the company shows revenue growth in its core software business and has a strong cash position, the significant net losses from continuing operations and the large loss from the discontinued operations sale warrant caution. The divestiture may lead to a more focused strategy, but the path to profitability needs to be demonstrated. Investors should monitor future performance and the impact of strategic shifts.

Keywords

biosimulation, drug discovery, regulatory science, model-informed drug development, software, consulting services, pharmaceutical industry, life sciences